These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 28534160)

  • 1. MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?
    Momtazi AA; Banach M; Pirro M; Stein EA; Sahebkar A
    Clin Rev Allergy Immunol; 2018 Apr; 54(2):224-233. PubMed ID: 28534160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular genetics of hypercholesterolemia].
    Schwarzová L
    Vnitr Lek; 2016; 62(11):877-881. PubMed ID: 28128573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.
    Grenkowitz T; Kassner U; Wühle-Demuth M; Salewsky B; Rosada A; Zemojtel T; Hopfenmüller W; Isermann B; Borucki K; Heigl F; Laufs U; Wagner S; Kleber ME; Binner P; März W; Steinhagen-Thiessen E; Demuth I
    Atherosclerosis; 2016 Oct; 253():88-93. PubMed ID: 27596133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refinement of pathogenicity classification of variants associated with familial hypercholesterolemia: Implications for clinical diagnosis.
    Di Costanzo A; Minicocci I; D'Erasmo L; Commodari D; Covino S; Bini S; Ghadiri A; Ceci F; Maranghi M; Catapano AL; Gazzotti M; Casula M; Montali A; Arca M
    J Clin Lipidol; 2021; 15(6):822-831. PubMed ID: 34756585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship.
    Sánchez-Hernández RM; Civeira F; Stef M; Perez-Calahorra S; Almagro F; Plana N; Novoa FJ; Sáenz-Aranzubía P; Mosquera D; Soler C; Fuentes FJ; Brito-Casillas Y; Real JT; Blanco-Vaca F; Ascaso JF; Pocovi M
    Circ Cardiovasc Genet; 2016 Dec; 9(6):504-510. PubMed ID: 27784735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectrum of mutations of familial hypercholesterolemia in the 22 Arab countries.
    Alhababi D; Zayed H
    Atherosclerosis; 2018 Dec; 279():62-72. PubMed ID: 30415195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No genetic linkage or molecular evidence for involvement of the PCSK9, ARH or CYP7A1 genes in the Familial Hypercholesterolemia phenotype in a sample of Danish families without pathogenic mutations in the LDL receptor and apoB genes.
    Damgaard D; Jensen JM; Larsen ML; Soerensen VR; Jensen HK; Gregersen N; Jensen LG; Faergeman O
    Atherosclerosis; 2004 Dec; 177(2):415-22. PubMed ID: 15530918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Congenital disorders of lipoprotein metabolism].
    März W; Grammer TB; Delgado G; Kleber ME
    Herz; 2017 Aug; 42(5):449-458. PubMed ID: 28555288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphisms in LDLR, APOB, PCSK9 and other lipid related genes associated with familial hypercholesterolemia in Malaysia.
    Lye SH; Chahil JK; Bagali P; Alex L; Vadivelu J; Ahmad WA; Chan SP; Thong MK; Zain SM; Mohamed R
    PLoS One; 2013; 8(4):e60729. PubMed ID: 23593297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LDLR and PCSK9 3´UTR variants and their putative effects on microRNA molecular interactions in familial hypercholesterolemia: a computational approach.
    de Freitas RCC; Bortolin RH; Borges JB; de Oliveira VF; Dagli-Hernandez C; Marçal EDSR; Bastos GM; Gonçalves RM; Faludi AA; Silbiger VN; Luchessi AD; Hirata RDC; Hirata MH
    Mol Biol Rep; 2023 Nov; 50(11):9165-9177. PubMed ID: 37776414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of familial hypercholesterolemia-associated genes on the phenotype of premature myocardial infarction.
    Lee C; Cui Y; Song J; Li S; Zhang F; Wu M; Li L; Hu D; Chen H
    Lipids Health Dis; 2019 Apr; 18(1):95. PubMed ID: 30971288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel type of familial hypercholesterolemia: double heterozygous mutations in LDL receptor and LDL receptor adaptor protein 1 gene.
    Tada H; Kawashiri MA; Ohtani R; Noguchi T; Nakanishi C; Konno T; Hayashi K; Nohara A; Inazu A; Kobayashi J; Mabuchi H; Yamagishi M
    Atherosclerosis; 2011 Dec; 219(2):663-6. PubMed ID: 21872251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study.
    Pirillo A; Garlaschelli K; Arca M; Averna M; Bertolini S; Calandra S; Tarugi P; Catapano AL;
    Atheroscler Suppl; 2017 Oct; 29():17-24. PubMed ID: 28965616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetically Confirmed Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome.
    Amor-Salamanca A; Castillo S; Gonzalez-Vioque E; Dominguez F; Quintana L; Lluís-Ganella C; Escudier JM; Ortega J; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
    J Am Coll Cardiol; 2017 Oct; 70(14):1732-1740. PubMed ID: 28958330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnosis and Treatment of Familial Hypercholesterolemia].
    Schöb M; Müller P; Gerth Y; Korte W; Rickli H; Brändle M; Bärlocher A; Bilz S
    Praxis (Bern 1994); 2018 Nov; 107(24):1345-1353. PubMed ID: 30482120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
    Saavedra YG; Dufour R; Davignon J; Baass A
    Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased LDL-C levels in a latvian population.
    Radovica-Spalvina I; Latkovskis G; Silamikelis I; Fridmanis D; Elbere I; Ventins K; Ozola G; Erglis A; Klovins J
    BMC Med Genet; 2015 Sep; 16():86. PubMed ID: 26415676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic Spectrum of Familial Hypercholesterolaemia in the Malaysian Community: Identification of Pathogenic Gene Variants Using Targeted Next-Generation Sequencing.
    Razman AZ; Chua YA; Mohd Kasim NA; Al-Khateeb A; Sheikh Abdul Kadir SH; Jusoh SA; Nawawi H;
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hyperlipoproteinemia and dyslipidemia as rare diseases. Diagnostics and treatment].
    Češka R; Štulc T; Votavová L; Schwarzová L; Vaclová M; Freiberger T
    Vnitr Lek; 2016; 62(11):887-894. PubMed ID: 28128575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial hypercholesterolemia modeling, CRISPR/Cas-mediated genetic correction, and productive hepatitis C virus infection.
    Caron J; Pène V; Tolosa L; Villaret M; Luce E; Fourrier A; Heslan JM; Saheb S; Bruckert E; Gómez-Lechón MJ; Nguyen TH; Rosenberg AR; Weber A; Dubart-Kupperschmitt A
    Stem Cell Res Ther; 2019 Jul; 10(1):221. PubMed ID: 31358055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.